CYP
Cynata Therapeutics Limited
1 day chart
About CYP
Cynata Therapeutics Limited (CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus, a proprietary therapeutic stem cell platform technology.
Buy Australian shares starting with CYP. Invest today with a CHESS-sponsored investing platform!
Market Capitalisation
$21M
Price-earnings ratio
-1.12
Dividend yield
NaN%
High today
$0.13
Low today
$0.12
Open price
$0.12
52-week high
$0.36
52-week low
$0.11
Announcements
CYP FAQs
Can I buy CYP shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?
Yes, the Stake platform allows you to buy CYP shares and over 8,000 stocks and ETFs across the ASX and Wall St.
How much is one share of Cynata Therapeutics Limited?
One share of Cynata Therapeutics Limited is valued at $0.13.
What is the ticker symbol for Cynata Therapeutics Limited?
The ticker symbol for Cynata Therapeutics Limited is CYP.
How do I buy CYP shares in Australia?
To buy CYP stocks in Australia you'll need to open an account with an investing platform like Stake.
To do so follow these steps:
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake AUS
- Deposit directly into your Stake wallet and you're ready to invest in CYP
What is the 52-week high for Cynata Therapeutics Limited stock?
The Cynata Therapeutics Limited 52-week high stock price is $0.36.
What is the 52-week low for Cynata Therapeutics Limited stock?
The Cynata Therapeutics Limited 52-week low stock price is $0.11.
What is the market capitalisation of Cynata Therapeutics Limited CYP?
As of 06/12/2023 Cynata Therapeutics Limited has a market cap of $21M.
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.